Development of factor IX inhibitor in an adult with severe haemophilia B following COVID-19 vaccination: A case report.
作者信息
Chiasakul Thita, Kessler Craig M
机构信息
Division of Haematology/Oncology, Georgetown University Medical Centre, Lombardi Comprehensive Cancer Centre and the Centre for Bleeding Disorders, Washington, DC, USA.
Division of Haematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
出版信息
Haemophilia. 2022 May;28(3):e83-e85. doi: 10.1111/hae.14542. Epub 2022 Mar 8.
PMID:35263491
Abstract
摘要
相似文献
1
Development of factor IX inhibitor in an adult with severe haemophilia B following COVID-19 vaccination: A case report.
Haemophilia. 2022 May;28(3):e83-e85. doi: 10.1111/hae.14542. Epub 2022 Mar 8.
2
Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia.
Hamostaseologie. 2021 Jun;41(3):190-196. doi: 10.1055/a-1401-2691. Epub 2021 Apr 15.
3
EHL-FIX in haemophilia B carriers with FIX deficiency.
Haemophilia. 2020 Mar;26(2):e38-e40. doi: 10.1111/hae.13906. Epub 2019 Dec 15.
4
The sudden and unexpected appearance of inhibitors in a previously treated severe haemophilia B patient after the switch to albutrepenonacog alpha.
Haemophilia. 2018 Sep;24(5):e372-e375. doi: 10.1111/hae.13590. Epub 2018 Aug 8.
5
Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
Haemophilia. 2018 May;24(3):414-419. doi: 10.1111/hae.13432. Epub 2018 Feb 5.
6
A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease.
Thromb Haemost. 1977 Feb 28;37(1):86-90.
7
The management of hemophilia patients with inhibitors.
Transfus Med Rev. 1992 Oct;6(4):285-93. doi: 10.1016/s0887-7963(92)70185-0.
8
The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Haemophilia. 2008 Sep;14(5):923-30. doi: 10.1111/j.1365-2516.2008.01810.x. Epub 2008 Jul 14.
9
Switching haemophilia products and inhibitor risk: a United States' perspective.
Eur J Haematol. 2015 Apr;94(4):283. doi: 10.1111/ejh.12441.
10
Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.
J Intern Med. 1992 Jul;232(1):25-32. doi: 10.1111/j.1365-2796.1992.tb00546.x.
Zotero 插件